 | |
| Clinical data | |
|---|---|
| Trade names | Xcopri, Ontozry |
| Other names | YKP3089 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620021 |
| License data |
|
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ≥88% |
| Protein binding | 60% |
| Metabolism | Mainly glucuronidation via UGT2B7 |
| Elimination half-life | 50–60 hours |
| Excretion | Mainly via urine |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C10H10ClN5O2 |
| Molar mass | 267.67 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cenobamate, sold under the brand name Xcopri and Ontozry, is a medication used to treat epilepsy, specifically focal-onset seizures.[1] It may be used together with other medication.[3] It is taken by mouth.[1]
Common side effects include sleepiness, dizziness, tiredness, double vision, and headache.[1] Other side effects may include short QT, DRESS, and suicide.[1] Use in pregnancy may harm the baby.[1] How it works is not entirely clear; however, it alters ion channels.[1]
Cenobamate was approved for medical use in the United States in 2019 and Europe in 2021.[4][3] It is on Schedule V of the Controlled Substances Act.[5] In the United States 30 pills of 100 mg costs about 1,000 USD as of 2022.[6]
References edit
- ^ a b c d e f g h i "Xcopri Titration Pack- cenobamate kit Xcopri- cenobamate tablet, film coated Xcopri Maintenance Pack- cenobamate kit". DailyMed. Archived from the original on 11 August 2020. Retrieved 1 February 2021.
- ^ "Schedules of Controlled Substances: Placement of Cenobamate in Schedule V". Federal Register. 10 March 2020. Archived from the original on 3 April 2021. Retrieved 4 August 2021.
- ^ a b c "Ontozry EPAR". European Medicines Agency (EMA). 25 January 2021. Archived from the original on 4 June 2021. Retrieved 4 June 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ "Cenobamate Monograph for Professionals". Drugs.com. Retrieved 3 January 2022.
- ^ "2020 - Placement of Cenobamate in Schedule V". DEA Diversion Control Division. 10 March 2020. Archived from the original on 19 April 2020. Retrieved 11 March 2020.
- ^ "Xcopri Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 19 October 2021. Retrieved 3 January 2022.